| Literature DB >> 33017014 |
Satoshi Kamiya1, Hiroya Takeuchi2, Kazumasa Fukuda1, Hirofumi Kawakubo1, Naoto Takahashi3, Norio Mitsumori4, Masanori Terashima5, Hironori Tsujimoto6, Shinichi Kinami7, Shoji Natsugoe8, Masaki Ohi9, Shinichi Kadoya10, Sachio Fushida11, Hideki Hayashi12, Kazuhito Nabeshima13, Junichi Sakamoto14, Satoru Matsuda1, Shuhei Mayanagi1, Tomoyuki Irino1, Yasunori Sato15, Yuko Kitagawa1.
Abstract
This prospective multicenter non-randomized phase III study aims to evaluate the long-term outcome of sentinel node navigation surgery for early gastric cancer compared with conventional distal or total gastrectomy. Clinically diagnosed primary T1N0M0 gastric cancer patients with a single lesion (≤40 mm) and without previous endoscopic treatment will be enrolled in this study. Sentinel nodes are identified by dye and radioisotope tracers and are subjected to intraoperative rapid pathology. For patients with negative sentinel node metastasis, individualized surgery consisting of limited stomach resection and sentinel node basin dissection is performed, while standard gastrectomy with D2 lymph node dissection is employed for the positive sentinel node patients. A total of 225 patients will be accrued from 13 hospitals that have experience in sentinel node mapping. The primary endpoint is 5-year relapse-free survival. The secondary endpoints are overall survival, sentinel node detection rate, diagnostic accuracy for sentinel node, distribution of sentinel nodes and metastatic sentinel node/non-sentinel node, and postoperative quality of life.Entities:
Keywords: clinical trial; phase III; precision medicine; sentinel lymph node; stomach neoplasms
Mesh:
Year: 2021 PMID: 33017014 DOI: 10.1093/jjco/hyaa179
Source DB: PubMed Journal: Jpn J Clin Oncol ISSN: 0368-2811 Impact factor: 3.019